NBC Los Angeles14h
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
GlobalData on MSN15h
Struggling bluebird bio to go private for less than $30m
Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...
ENDPOINTS NEWS16h
Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies
A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...
Blue Bird Corporation: An Opportunity To Hitch A Ride To Strong Upside
Blue Bird Corporation is a compelling investment due to its focus on electric school buses and attractive stock valuation despite recent performance setbacks. Read more here.
TMCnet19h
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders
The transaction agreement unreasonably limits competing transactions for bluebird by imposing a significant penalty if bluebird accepts a competing bid. We are investigating the conduct of bluebird's ...